Skip to main content

Table 4 Individual RTV plasma concentrations in patients treated with RBT 150 mg TPW or RBT 300 mg TPW

From: Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

PatientsSexAge (years)Weight (kg)C0 (µg/mL)C1C2C3C4C6C8C12AUC0–12 (µg h/mL)Cl(L/h/kg)CmaxTmax
First group (RBT 150 mg TPW)
 Patient1F3950.51.20.41.70.641.280.72.40.27.80.251.284
 Patient3M3656.82.11.862.50.40.5111.338.90.191.861
 Patient5M4345.21.4322.241.812.261.421.51.712.80.172.264
 Patient7M32442.11.561.561.261.32.741.911.712.20.182.746
 Patient9F39362.962.52.873.162.742.421.932.8418.50.153.163
 Patient11F3357.67.5810.310.811.510.78.28.367.40.0311.54
 Patient13M34551.851.911.721.651.21.641.241.110.80.171.911
 Patient15M24524.113.83.63.52.73.32.83.623.50.083.62
 Patient17M47603.13.12.62.91.71.51.20.614.80.112.93
Second group (RBT 300 mg TPW)
 Patient2F3340LowLow11.331.441.221.10.626.40.391.444
 Patient4M44550.410.370.40.30.380.30.28low2.20.810.42
 Patient6F3340.10.2Low0.80.80.90.80.90.64.60.540.94
 Patient8M3260.82.721.972.221.410.951.450.660.5310.30.162.222
 Patient10F3240.21.842.142.432.41.671.310.712.20.202.432
 Patient12F2549.21.551.641.91.922.521.8613.60.152.56
 Patient14F44522.31.51.121.210.50.13Low6.60.291.51
  1. RBT rifabutin, TPW three times per week, LPV lopinavir, RTV ritonavir, Cn drug plasma concentration at the specified time, Cmax maximum (peak) plasma drug concentration, Tmax time to reach maximum (peak) plasma concentration following drug administration, C0 plasma drug concentration before the morning dose, C12 plasma drug concentration before the evening dose (12 h post-dose)